Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

Key Takeaway: Silence Therapeutics presented follow-up data on Divesiran at EHA 2026, showcasing its durable efficacy in treating Polycythemia Vera. The data suggests a potential best-in-class profile for the treatment. Further details on the study's outcomes and implications were not provided in the article.